Skip to content
Search

Latest Stories

Over 90% of UK pharmacists report increased workload in past year, survey finds

Only 22% of UK pharmacists feel valued by policymakers
pharmacist discussing medication with senior customer (gettyimages)

Only one in five UK pharmacists feel their vital frontline healthcare role is valued by policymakers

A new survey has highlighted growing concerns about pharmacists’ increasing workload and their often-overlooked role within the healthcare systems.

In the survey commissioned by consumer health company Kenvue, over 90 per cent of pharmacists reported a workload increase over the past year, with only 37 per cent considering their current workload sustainable.


Their primary concerns include the impact of workload on wellbeing, expanding clinical roles and services, and challenges with staff recruitment and retention.

Pharmacists reported spending most of their time advising patients on common ailments such as coughs, colds, pain, and allergies. However, they spend significantly less time on preventive services, which could further reduce pressure on the wider healthcare system.

For instance, only seven pharmacists focus primarily on smoking cessation, and just four per cent on oral health.

The survey also highlighted pharmacists' sense of being undervalued, with only 22 per cent feeling valued by policymakers, despite their significant contributions to primary care provision.

Notably, 97 per cent of pharmacists indicated that patients seek their advice because they are unable to secure GP appointments.

The findings suggested the need for greater recognition and support for the profession within the healthcare system.

Manoj Raghunandanan, area managing director of Northern Europe at Kenvue, said: "At a time when the healthcare system is under significant pressure and securing a GP appointment is a challenge for many, this survey emphasises the vital role pharmacists continue to play in the UK’s healthcare landscape.

“But it also unfortunately underscores the urgent need for change in how pharmacists are valued and supported within the wider healthcare framework.”

He added that there is a risk of pharmacists' role and trusted community position being overlooked and taken for granted at times.

The survey suggested that, with the right support in place, pharmacists are well-placed to advance government health priorities, particularly in the shift towards community care and preventive healthcare.

Nearly 90 per cent of pharmacists surveyed believe many health issues could be prevented through better self-care, while 80 per cent think improved consumer education would help achieve this goal.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less